title: Event-related potentials in Parkinson's disease: a 12-month follow-up study.
abstract: Auditory event-related potentials were recorded using the oddball paradigm in 26 patients with Parkinson's disease, all treated with L-Dopa. The latency of the P3 wave was significantly greater than in an age-matched controls, and was also correlated with the disease duration, but not with scores on two scales measuring cognitive deficit. One year later, when treatment with a dopaminergic agonist, bromocriptine 20-30 mg/day, had been added to the therapeutic regimen, N2 and P3 latencies had increased, whereas several clinical parameters had improved. Thus a longer P3 latency does not seem to be linked to a global cognitive deficit. The use of neuropsychological tests exploring more limited tasks should show the prospective utility of event-related potentials in Parkinson's disease.
authors.affiliation: Service de Neurologie, CHU Jean Minjoz, Besançon, France.
authors.forename: L
authors.initials: L
authors.lastname: Rumbach
authors.forename: C
authors.initials: C
authors.lastname: Tranchant
authors.forename: J F
authors.initials: JF
authors.lastname: Viel
authors.forename: J M
authors.initials: JM
authors.lastname: Warter
mesh_terms: D000328:Adult; D000368:Aged; D001971:Bromocriptine / Q000627:therapeutic use; D003071:Cognition / Q000502:physiology; D004359:Drug Therapy, Combination; D005072:Evoked Potentials, Auditory / Q000502:physiology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy / Q000503:physiopathology*; D011446:Prospective Studies
chemical_list: D001971:Bromocriptine; D007980:Levodopa